Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicadrostat and Empagliflozin in Chronic Kidney Disease
NCT06926660Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Placebo followed by vicadrostat/empagliflozin with Vicadrostat/empagliflozin (2 arms). Primary endpoint: Absolute change in estimated glomerular filtration rate at 16 weeks. Started Jul 2025; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06926660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926660.